SBIR/STTR Research Award

An Anti-Cancer Immunoadhesin Made in Plants

Award identifier e087c06439a0bd0f41693109e0b0fe8cbfc7ddbd2bd345f409f0270d12c33ca8Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$159,450

Program and phase

SBIR · Phase I

Award year

2008

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Planet Biotechnology Incorporated
Proposal award date
Not reported
Contract end date
Not reported
UEI
KTJKPBE2H5H3
Solicitation number
PHS2007-2
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): The growth and metastasis of tumors depends, to a large extent, on the development of new blood vessels to supply food and oxygen to rapidly growing and dividing cells. Proteins involved in angiogenesis are attractive t argets for new cancer therapeutics. One protein in particular, tumor endothelial marker 8 (TEM8), appears to be expressed exclusively, in adults, in the endothelial cells lining tumor blood vessels. A recent report found that a fusion of TEM8 and the Fc po rtion of IgG (TEM8-Fc) was a potent anti-cancer agent in a mouse model against a range of human tumor types. The overall goal of this Phase I project is to produce, using a rapid and transient plant expression system, forms of TEM8-Fc that will have enhanc ed binding to certain receptors on immune effector cells. Improvements in receptor binding will be achieved through both glycoform and amino acid engineering of the recombinant protein. We will then test the hypothesis that the anti-tumor activity of TEM8- Fc is related to its ability to mediate antibody dependent cellular cytotoxicity (ADCC) of cells expressing surface TEM8. Comparisons of ADCC activity will be followed by comparisons of anti-tumor activity in a nude mouse xenotransplantation model. Transge nic plants are a promising platform for the large-scale production of antibodies and other therapeutic proteins for treating serious and life-threatening conditions, including cancer. The advantages of using plants, rather than genetically modified animal cells in bioreactors, include very low cost of goods, and safety, due to the inability of plants to be infected with mammalian viruses and prions. Production in tobacco, a plant not used in the human food chain, avoids concerns about adventitious presence of therapeutic proteins in food or feed. In addition, the amount of protein that can be produced per acre with tobacco far exceeds what is possible with a seed crop like corn. Costs of purification, however, are similar to that of proteins produced in mamm alian cell culture. The long-term goal is to develop TEM8-Fc into a highly effective, safe and economical treatment for a wide range of metastatic cancers. PUBLIC HEALTH RELEVANCE: New and more effective therapies for cancer are needed. This project would examine the mechanism of action of a novel recombinant protein that inhibits angiogenesis and growth of tumors, and should identify modifications to the protein that will make it even more effective at lower doses. Expression of this protein in plants will allow highly economical, large scale and safe production, making cancer therapy using dosages of a gram or greater of this recombinant protein much more available.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

38 SBIR/STTR records share this UEI (2000–2024). Reported award amounts total $26,790,475. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services, Department of Defense, Department of Agriculture

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.